心脏保护性中药与抗逆转录病毒药物代谢:体外证据的系统综述
该综述评估丹参、黄芪、白术、当归、川芎和甘草六种心脏保护性中药对代谢抗逆转录病毒药物的CYP酶表达和活性的影响。纳入24项体外研究,偏倚风险低;丹参和甘草研究最多,水提物中丹参对CYP活性影响小,甘草有抑制潜力,其他中药倾向诱导酶。提示需关注中药-抗逆转录病毒药物相互作用。
要点
- 丹参水提物对CYP活性影响小,与抗逆转录病毒药物联用可能相对安全。
- 甘草水提物有抑制CYP酶潜力,联用抗逆转录病毒药物需谨慎。
- 黄芪、当归、白术、川芎水提物倾向诱导CYP酶,可能降低抗逆转录病毒药物暴露。
核心结论
- 中药在管理HIV患者炎症共病方面潜力大,但需仔细考虑中药与抗逆转录病毒药物的相互作用。
- 丹参与抗逆转录病毒治疗联用可能相对安全,其他中药需谨慎。
- 临床相关提取方法及全方研究对评估中药-药物相互作用至关重要。
研究设计与样本
- 系统综述体外实验室研究,检索并筛选出24篇符合纳入标准的文献。
- 评估丹参、黄芪、白术、当归、川芎和甘草六种中药提取物及参照活性分子对CYP表达和酶活性的影响。
- 使用SciRAP 2.1偏倚风险工具评估研究质量,总体偏倚风险低。
主要发现
- 共鉴定426篇文章,24篇符合纳入标准。
- 丹参和甘草是研究最多的中药。
- 对酶活性无显著影响是最常见结果:丹参占61%的试验,甘草37%,当归47%,黄芪67%。
- 丹参水提物对CYP活性影响极小,甘草水提物显示潜在酶抑制。
- 其他中药水提物显示酶诱导趋势。
临床怎么用
- HIV患者使用心脏保护性中药时,应评估与抗逆转录病毒药物的相互作用风险。
- 丹参可能相对安全,但甘草及其他中药需谨慎联用。
- 关注中药提取方法对相互作用研究的影响,优先参考水提物证据。
局限性
- 证据仅来自体外研究,需临床研究验证。
- 仅评估六种中药,未覆盖所有心脏保护性中药。
- 多数研究未使用全方,单味药结果可能不能完全反映复方效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: There is considerable potential for using Chinese Herbal Medicine to manage inflammatory co-morbidities, including cardiovascular disease, in people with HIV. However, any use would require understanding herb-drug interactions with antiretroviral (ARV) drugs to ensure safety. We evaluate evidence for the effect of selected cardioprotective Chinese herbs on the activity of cytochrome P450 (CYP) enzymes that metabolise ARV drugs. METHODS: We conducted a comprehensive review of six Chinese herbs commonly found in Chinese herbal formulas for treating cardiovascular conditions. We examined the effects of their extracts and reference bioactive molecules on CYP expression and enzymatic activity. The review focused on evidence from in vitro laboratory studies. The included herbs were Dan Shen, Huang Qi, Bai Zhu, Dang Gui, Chuan Xiong, and Gan Cao. Study quality was assessed using the SciRAP 2.1 risk of bias tool, and results were grouped according to experimental methodology. RESULTS: 426 articles were identified of which 24 met the inclusion criteria. Overall risk of bias was low. Dan Shen and Gan Cao were the most frequently studied herbs. The most common outcome reported was no significant effect on enzyme activity, occurring in 61% of assays for Dan Shen, 37% for Gan Cao, 47% for Dang Gui, and 67% for Huang Qi. Aqueous extracts, representing the most clinically relevant preparation, of Dan Shen had minimal impact on CYP activity, while those of Gan Cao indicated potential for enzyme inhibition. In contrast, aqueous extracts of the other herbs showed a tendency toward enzyme induction. DISCUSSION: These findings suggest that there is great potential for use of Chinese herbal medicine in managing inflammatory co-morbidities in people with HIV, but that careful consideration of herb-ARV drug interaction is warranted. While Dan Shen appears relatively safe to use in individuals receiving ARV therapy, caution is warranted for other herbs. We highlight the importance of clinically relevant extraction methods in herb-drug interaction studies. Since individual herbs may have opposing effects on ARV drug metabolism, studies conducted using whole formulae are critical.
引用
- Cheng WJ, Jaworowski A, Trevillyan JM, et al. Cardioprotective Chinese herbs and antiretroviral drug metabolism: a systematic review of in vitro evidence. Front Pharmacol. 2025. PMID: 41357858. doi:10.3389/fphar.2025.1627058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。